CN Patent

CN120202007A — 用于治疗转移性癌症的与抗血管生成剂组合的plk1抑制剂

Assigned to Cardiff Cancer Technology Co ltd · Expires 2025-06-24 · 1y expired

What this patent protects

提供的包括用于治疗受试者中转移性癌症的方法、组合物和试剂盒。方法可以包括以足以减少或抑制转移性癌症进展的方式向尚未接受既往抗血管生成治疗的受试者施用包括抑制血管生成的治疗和PLK1抑制剂(例如，onvansertib)。

USPTO Abstract

提供的包括用于治疗受试者中转移性癌症的方法、组合物和试剂盒。方法可以包括以足以减少或抑制转移性癌症进展的方式向尚未接受既往抗血管生成治疗的受试者施用包括抑制血管生成的治疗和PLK1抑制剂(例如，onvansertib)。

Drugs covered by this patent

Patent Metadata

Patent number: CN120202007A
Jurisdiction: CN
Classification: —
Expires: 2025-06-24
Drug substance claim: No
Drug product claim: No
Assignee: Cardiff Cancer Technology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.